Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
about
The role of Src in solid tumorsS100β as a serum marker in endocrine resistant breast cancer.Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins.Elevated c-Src and c-Yes expression in malignant skin cancersNovel dual Src/Abl inhibitors for hematologic and solid malignancies.Dasatinib induces autophagic cell death in human ovarian cancer.Predictive biomarkers for dasatinib treatment in melanoma.A phase 2 trial of dasatinib in advanced melanoma.Improved angiostatic activity of dasatinib by modulation with hydrophobic chainsExpression and functional role of CRIPTO-1 in cutaneous melanoma.Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaFluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusActivity of the multikinase inhibitor dasatinib against ovarian cancer cellsSRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Current status of SRC inhibitors in solid tumor malignancies.Targeted therapy for melanoma: rational combinatorial approaches.Involvement of autophagy in cervical, endometrial and ovarian cancer.A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin.Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Targeting invasive properties of melanoma cells.Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.Hypothermia-induced tyrosine phosphorylation of SIRPα in the brain.Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling.A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
P2860
Q24616659-60727969-F451-4CC3-8578-83620425E9A0Q33556608-F3F7ACD5-9C9C-4F45-B0AB-0A44E5D160D1Q33642206-943E561A-9B34-4B0C-A19A-D0C8EA9D0DACQ34114252-F26EE88E-B929-472F-89B4-2664152E15AEQ34121339-FC4FE2A3-DBD3-4FD5-A03D-BC14DAE25A72Q34286944-4FAF1245-72D0-4E15-B412-36B25E4E3CFBQ34781153-57385577-2419-4AAF-80DB-EB29FDB9E3C3Q35048145-D2D1CEC6-8384-4FD8-928F-8675AAC85083Q35178869-9AC578DE-9D3B-40D1-ABCD-A983AB4B2F0BQ35262949-1AF6EBF5-A89E-436A-86E3-D97475D38CEDQ35653813-7549749F-AD28-4763-A0F0-88CFCB35B444Q36520705-94949627-A2C3-42EC-9451-4EAC2B2FE1A5Q36560775-5E54D046-DBEC-419B-B5DE-7C7A37EDCC0BQ37424063-0D4F3881-66F9-4E6C-97D4-73B4B9B97511Q37509699-731C9CCE-4470-4B9D-B325-F561ECB0ABE0Q37613072-4FDB4649-4475-4B59-AB33-8A599743B90EQ37869271-8232244B-0F20-4559-BBAD-54A99D591F7EQ38082327-10DF5EF5-770B-4B63-974E-879296F5D03DQ38152325-EC391A52-8895-443B-BB44-4917CFE1E50FQ38294800-A9F1D7BD-4548-40C7-98AA-D147888208A7Q38942848-AD9F368A-5006-4CFF-8213-45E5BE7C17D9Q39107981-AD73BB10-247F-4F66-8849-B76602D68021Q39135139-B0FC8F1D-3084-4EA8-8AF0-B260844471B8Q39250672-9F45F685-66CB-4C3F-A5F5-1326EEEBB56CQ39412894-CA056852-2574-4D6E-984D-2C4A1C47C854Q39434943-47E8546C-DEED-4D54-8CD5-1DEF3CE7C99FQ39507461-79033635-275E-4603-8C12-217127E09338Q42206973-2B789A14-1B5B-40F0-A0D9-79DE8A13A11EQ42504354-DD6079B9-8049-459E-AF88-153465506620Q43247067-BA642A05-E1BA-4053-8D30-2354C0F74DB1Q46780069-74B0C9AA-ABCF-45D8-A3D9-E5A7B2B1B147Q48138303-85BD02A0-1B61-4877-ADFB-8BC7ED4517C1Q51023478-EE7F625F-6DC4-4666-BF77-7AF8A1837DFF
P2860
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Preclinical evaluation of dasa ...... ibitor, in melanoma cell lines
@en
type
label
Preclinical evaluation of dasa ...... ibitor, in melanoma cell lines
@en
prefLabel
Preclinical evaluation of dasa ...... ibitor, in melanoma cell lines
@en
P2860
P356
P1476
Preclinical evaluation of dasa ...... ibitor, in melanoma cell lines
@en
P2093
John Crown
Martin Clynes
P2860
P2888
P356
10.1186/1479-5876-6-53
P577
2008-09-29T00:00:00Z